ADAPT-BLADDER Cohort 4: A Phase 1/2 Trial of Durvalumab Plus Intravesical Gemcitabine and Docetaxel in BCG-Unresponsive NMIBC

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Noah Hahn, MD, of Johns Hopkins Medicine discussed cohort 4 of the ADAPT-BLADDER study, which examined durvalumab in combination with intravesical gemcitabine and docetaxel for patients with BCG-unresponsive NMIBC.

He elaborates on the study’s beneficial complete response rates and how it compares to results from other studies, and how to navigate potential disease progression in the study’s patient population.